Publications by authors named "James K George"
Zika virus (ZIKV) serological diagnostics are compromised in areas where dengue viruses (DENV) co-circulate because of their high levels of protein sequence homology. Here, we describe the characterization of a Zika blockade-of-binding ELISA (Zika BOB) and a Zika microneutralization assay (Zika MN) for the detection of ZIKV nonstructural protein 1 (NS1)-specific antibodies and ZIKV neutralizing antibodies, respectively. Zika BOB and Zika MN cutoffs were established as 10 and 100 endpoint titers, respectively, using samples collected pre- and post-virologically confirmed ZIKV infection from subjects living in DENV-endemic areas.
View Article and Find Full Text PDFDengue virus (DENV) infections elicit antibody responses to the non-structural protein 1 (NS1) that are associated with protection against disease. However, the antibody isotypes and subclasses involved, and their kinetics have not been extensively studied. We characterized the antibody responses to DENV NS1 by enzyme-linked immunosorbent assay (ELISA) in a longitudinal cohort of 266 confirmed dengue cases in Recife, Northeast Brazil.
View Article and Find Full Text PDFArticle Synopsis
- Dengue virus infection triggers immune responses, including the production of antibodies against non-structural protein 1 (NS1), detectable soon after infection.
- The CYD-TDV vaccine, developed by Sanofi Pasteur, is a live, attenuated vaccine that does not express NS1, prompting an evaluation of NS1-specific IgG antibodies as indicators of dengue exposure in individuals vaccinated with CYD-TDV.
- A quantitative ELISA for anti-dengue NS1 IgG showed high accuracy in identifying past dengue infections, achieving over 93% agreement in serostatus classification in paired samples, though some misclassification occurred potentially due to asymptomatic infections and variations in the assay results.